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Abstract
Background & objectives: During 2006, chikungunya emerged as a major ever known epidemic in
India. Disability adjusted life years (DALY) is an appropriate summary measure of population
health to express epidemiological burden of diseases. We estimated the burden due to suspected
chikungunya using DALYs for the first time and compared between the states and also with the
burden due to other vector-borne diseases in India. The economic burden was also assessed in terms
of productivity loss.
Methods: Data on the reported cases of fever/suspected cases of chikungunya from different states
during 2006 in India were used. Years lived with disability (YLD) were calculated for non-fatal
cases to estimate DALY. Since the disability weight for chikungunya is not available, the weights
available for rheumatic arthritis, comparable to the disease outcome of chikungunya were used for
the estimation. The burden was estimated for both acute and chronic cases. It is considered that
about 11.5% of cases were reported to have extended morbidity with persisting arthralgia. For
acute disease, the average duration of illness was considered to be nine days and for chronic cases
it was six months on an average. The productivity loss due to income foregone by the working class
was calculated using minimum official wage.
Results: National burden of chikungunya was estimated to be 25,588 DALYs lost during 2006
epidemic, with an overall burden of 45.26 DALYs per million. It varied from 0.01 to 265.62 per
million in different states. Karnataka alone contributed as high as 55% of the national burden.
Persistent arthralgia was found to impose heavy burden, accounting for 69% of the total DALYs.
The productivity loss in terms of income foregone was estimated to be a minimum of Rs. 391
million.
Interpretation & conclusion: The chikungunya epidemic in the year 2006 imposed heavy
epidemiological burden and productivity loss to the community. The burden of chikungunya in
terms of DALY was estimated for the first time. In view of re-emergence and spread of this infection
in recent times it is warranted for derivation of disability weight for different health states of
chikungunya to facilitate realistic estimates of DALYs. Quality epidemiological data from
surveillance system to monitor vector-borne and zoonotic diseases would pave way for more realistic
estimates of burden. The productivity loss in-terms of income foregone could be minimal as the
estimation was made by using the minimum wage fixed by the government although the actual loss
is expected to be higher.
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Introduction
Chikungunya is a mosquito-transmitted viral infec-
tion, affecting all in the community. It is caused by
alphavirus belonging to the family Togaviridae1,2. It
was first described in Tanzania in 19523 and has
since been found in Africa, India, and other South-
east Asian countries. The Asian isolate has been re-KRISHNAMOORTHY ET AL: BURDEN OF CHIKUNGUNYA IN INDIA  27
ported to be different genomically from that of the
African4,5.  Aedes aegypti, a mosquito that breeds in
domestic and peri-domestic containers and an
aggressive daytime biter is the primary vector of
chikungunya virus to humans in Asia6.  Aedes
albopictus which is prevalent in Asia is susceptible
to chikungunya virus and may play a role in the trans-
mission in this region7,8. Human is the only host
serving as reservoir of infection and transmission is
sustained by human-mosquito-human cycle through
primates9. No sylvatic (forest) cycle has been re-
ported in Asia as suggested in Africa. There is no
evidence for transovarial (vertical) transmission10.
But co-infection or dual infection with dengue has
been reported11,12. Mother to child transmission has
also been reported recently13. This disease is highly
infectious and cases explode in geometric propor-
tions. Since December 2005, chikungunya emerged
in epidemic proportions in India and a total of 1.39
million suspected cases have been reported14. As
many as 213 districts in 15 states were affected.
The burden due to illness can be expressed in many
ways. Though the number of cases and incidence will
indicate the magnitude and gravity of the problem for
a given health state, it is essential to use a summary
measure which considers all the health outcomes to
compare across diseases with varied clinical out-
comes. The disability adjusted life years (DALY)15
is one such summary measure of population health
which is being increasingly used in expressing the
burden due to diseases. It is a measure of the loss of
healthy days in a society due to mortality and mor-
bidity. This summary measure can compare the bur-
den across diseases, as well as across  populations.
It can also serve as a tool for resource allocation and
cost-effective analysis. Precise information about
diseases and injuries, their incidences, their conse-
quences including non-fatal health outcomes, their
causation and their trend is more than ever necessary
to inform policy-making. The power of using a com-
mon metric for burden assessment and economic
appraisal of intervention options warranted crafting
of a measure for both purposes16. The Global Bur-
den of Disease (GBD) study group as well as others
(Dengue) have reported DALYs for a number of vec-
tor-borne diseases17. A large number of studies
aimed at comparing the impact of intervention also
used DALY18. However, now here, estimates of bur-
den of chikungunya in terms of DALYs were made.
This may be due to lack of epidemiological data and
other input parameters. Therefore, data available on
the suspected chikungunya cases during the 2006
epidemic in different states14 were used to estimate
the burden due to chikungunya in terms of DALY
and the results are presented in this communication.
Material & Methods
Data base: The consolidated data base available
from the National Vector Borne Disease Control
Programme (NVBDCP) web site14 for the year 2006
was used for estimating the burden. It gives state wise
information on the number of districts affected,
total number of reported fever/suspected cases of
chikungunya, number of samples screened for
chikungunya and confirmed cases. Chikungunya in-
cidence was estimated based on the total population
in the affected districts of the respective states wher-
ever district wise information was available. Cases
with less than one month of illness were considered
as acute episodes and cases above one month dura-
tion of debilitating joint pain as persisting arthralgia.
Method of estimating DALY: Disability adjusted life
years (DALYs), a summary measure of population
health which combines time lived with disability and
the time lost due to premature mortality was used to
estimate the burden due to chikungunya in India.
DALYs were estimated using the method adopted by
Murray19 for estimating the global burden of dis-
eases15,20. The years of life lost (YLL) due to prema-
ture mortality and the years lived with disability
(YLD) are the two components of DALY. Though
mortality due to chikungunya has been re-
ported13,21,22, there was no data to support the cause
of death due to chikungunya for the 2006 epidemic
in India. Therefore, in the present estimation of
DALY, YLL is zero and it reflects only YLD. Since,
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gender is at the risk of infection and developing dis-
ease23,24, estimates were made without considering
the standard recommended age classes. Therefore,
we did not consider age weighting for the estimation.
Since, discount rate is shown to be an insignificant
factor25, we did not account for the future value of
health. Consequently, the YLD was calculated as the
product of the number of cases, disability weight and
duration of illness. The DALY was corrected to the
sero-positivity rate, and to ensure accuracy, the num-
ber of cases that had approached the private health
care facilities were also taken into account to estimate
the total number of chikungunya cases and DALY
estimation because a large proportion of people
(77.56%) (personal observation) could have utilized
private health care facilities which may not have been
reported under the current surveillance system.
The disability weight is a key component in YLD
estimation. It represents the severity of an illness and
can range from 0 to 1, where the value of 0 represents
healthy life and 1 represents death. The Global Dis-
ease Burden study group15 has derived disability
weights for 107 health states which are the outcomes
of different diseases26, in addition to disability
weights drawn independently for other health
states25. However, no disability weight is available
for a number of health states including chikungunya.
Therefore, we used the disability weight (0.233),
available for rheumatoid arthritis, the health outcome
of which is comparable with the case definition of
chikungunya22,27,28. This disease did not receive
adequate attention for deriving disability weight as
it was not common for decades. In case of non-avail-
ability of disability weight for a given health state,
the disability weight of health state of other disease
which are comparable to the health states of the dis-
ease in question are considered. For example, in a
study on inherited disorders of haemoglobin29, dis-
ability weights for anaemia caused by haemoglobin
disorders were taken from other causes of anaemia
for estimating the burden.  DALYs for acute episodes
and chronic cases (persistent arthralgia) were calcu-
lated separately and summed for total. It was reported
that about 11.5% of the cases had extended morbid-
ity with persistent arthralgia. The duration was re-
ported to range from six months to three years5. A
minimum duration of six months was used for cal-
culating YLD for chronic cases and for acute disease,
it was nine days.
Sensitivity analysis: Few assumptions were used in
the calculation of DALY because of some uncertain-
ties. They include: all those who suffered from
chikungunya had reported to public health care facili-
ties; all the suspected cases were due to chikungunya;
the mean duration of illness (acute and persistent
symptoms) represents the variation at population
level; and disability weight of arthritis is valid for
chikungunya. These uncertainties were subjected to
sensitivity analysis with varying values reported
from different studies. To account for unreported
cases, the number of reported cases, i.e. 1.39 million,
was multiplied by a set of factors. The multiplication
factor for incorporating the proportion of cases that
had reported to private health facilities [1.9 to 4.45
(personal observation)24, duration of acute episode
(1–30 days)30, duration of persistent arthralgia (6
months to 3 years)]5,31,32, disability weight (0.233 to
0.81)15,25 and the true positivity rate (2.7 to 100)14
based on confirmatory tests for chikungunya were
the parameters and values used in sensitivity analy-
sis (Table 1). The difference in DALYs that was es-
timated using the lowest and highest values of the
given parameter and the proportion to that of base
model was used to examine the extent of its influence
on DALY estimates. The change in DALY estimate
in relation to that estimated from base model was
compared between different parameters of uncertain-
ties to identify the most influential parameter.
The burden of chikungunya was compared against
the values reported by Global Burden of Disease
group17 for other vector-borne diseases in India af-
ter converting the total DALYs into DALYs per mil-
lion population.
Productivity loss: The individuals affected with
chikungunya remain incapacitated at least for a week,
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come due to illness was calculated for those who
were in the working age class. Since the primary data
on income forgone for the individuals suffering from
chikungunya were not available, the productivity loss
in terms of income-forgone was estimated using the
minimum official daily wage of Rs. 52.69 per indi-
vidual as per the rate fixed by the government33 and
nine days as the average number of working days lost
for both the genders. Therefore, the estimated pro-
ductivity loss is considered minimal. Since the age
distribution of the cases was not available, the popu-
lation age distribution of the working age group be-
tween 15 and 59 years of age of the respective state
was used to calculate the number of patients in the
working age group. Productivity loss was calculated
only for acute episodes for each state as the duration
of persistent arthralgia is highly variable5,34.
Results
Chikungunya affected at least 213 districts in 15
states in India during the year 2006.  Fig. 1 shows the
distribution of 168 districts for which details of
chikungunya cases are available. For four states
(Maharashtra, Tamil Nadu, Madhya Pradesh and
Rajasthan),  such district wise details were not avail-
able and the whole state population was considered
as under risk. The total population at risk of infection
was 565.41 million and the number of fever/sus-
pected chikungunya cases were as high as 1.39 mil-
lion and ranged between 35 (Lakshadweep) and
7,62,026 (Karnataka). The overall incidence per
thousand population was calculated to be 2.46 and it
ranged between 0.04 (NCT of Delhi) and 14.45
(Karnataka) (Table 2). The number of blood samples
screened for chikungunya varied between 6 and 5421
from different states and the positivity rate ranged
from 2.7 (Goa) to 100% (West Bengal and
Lakshadweep). Out of the total 15,504 samples
screened, 12.8% were positive for chikungunya.
When corrected to the sero-positivity rate, out of 1.39
million at least 0.148 million cases were definitely
due to chikungunya during 2006 epidemic.
The total DALY estimated was 25,588 due to
Table 1. Basic model of DALY estimation with values for various input parameters
Parameter Base  value Range Source (Reference)
Multiplication factor 1 1.96–4.45  24
Disability weight 0.233 0.233–0.81 25,  26
Duration of illness (acute days) 9  1–30 24, 30 
Duration of disability chronic (days) 6 months 6 months –3 year 5, 31
Proportion of persistent arthralgia 0.12 0.11–0.69 5, 34
Positivity rate (%) for chikungunya 100 2.7–100 14
Fig. 1: Districts reported with suspected cases of
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chikungunya in India. State-wise analysis showed
that the maximum DALYs lost was in Karnataka
14,007, followed by Maharashtra (4932) (Table 3).
Analysis of burden in relation to sequelae of this dis-
ease showed that acute episodes contributed only
7,909 DALYs (30.9%) and the persistent incapaci-
tating arthralgia accounted for the rest (69.1%), in-
dicating that major burden was imposed by the
chronic arthralgia. When DALY estimates were
made by computing the estimated number of con-
firmed cases (0.148 million), it was 2722. A large
proportion of cases (77.56%) were seeking care from
private health facilities, and hence, the number of
cases reported from public health information system
was underreported. When such underestimations
were corrected and estimated, the DALYs were as
high as 1,14,029.
Analysis of data on DALYs lost per million popula-
tion showed that the estimates were highly variable
(Table 3). It ranged between 0.005 (West Bengal)
and 265.62 (Karnataka). Though the total DALY was
only 82 in Andaman and Nicobar Islands, the DALY
per million was as high as 230.68, ranking it next to
Karnataka. Stratification of states in relation to
DALYs lost per million population (Fig. 2) showed
that Karnataka, Andaman and Nicobar Islands
and Maharashtra were at the maximum risk of
chikungunya.
Sensitivity analysis showed that since the proportion
Table 2. Population at risk, reported cases and incidence of fever/suspected chikungunya cases
during 2006 epidemic in India
State Total No. of Total Total fever No. of No. of Positivity Incidence
number of districts population cases/sus- samples confirmed rate (per 1000
districts affected pected screened cases population)
chikungunya
fever cases
Andhra Pradesh 23 23 7,57,27,541 77,535 1224 248 20.3 1.02
Karnataka 27 27 5,27,33,958 7,62,026 5000 298 6 14.45
Maharashtra 35 34 9,67,52,247 2,68,333 5421 786 14.5 2.77
Tamil Nadu* 40 35 6,21,10,839 64,802 648 116 17.9 1.04
Madhya Pradesh 45 21 6,03,85,118 60,132 892 106 11.9 1
Gujarat 25 25 5,05,96,992 76,012 1155 225 19.5 1.5
Kerala 14 14 3,18,38,619 70,731 235 43 18.3 2.22
A & N Islands 2 2 3,56,265 4469 0 0  NA 12.54
NCT of Delhi 12 12 1,37,82,976 560 560 67 12 0.04
Rajasthan 32 1 20,09,516 102 44 24 54.5 0.05
Puducherry** 4 1 7,35,004 542 52 9 17.3 0.74
Goa 2 2 13,43,998 287 75 2 2.7 0.21
Orissa 30 13 3,68,04,660 6461 171 34 19.9 0.18
West Bengal 18 1 8,01,76,197 NA 21 21 100 NA
Lakshadweep 2 60,650 35 6 6 100 0.58
Total 309 213 56,54,14,580 13,92,027 15,504 1985 12.8 2.46
*Out of total 40 administrative districts; **Affected district population; Source: National Vector Borne Disease Control
Programme (NVBDCP), Delhi (Available from: http://www.nvbdcp.gov.in/chikun-cases.html, accessed on 27 Nov 2006).KRISHNAMOORTHY ET AL: BURDEN OF CHIKUNGUNYA IN INDIA  31
of confirmed cases, choice of disability weight and
the proportion of cases that have availed treatment
from private health care sources were not known,
DALY estimates were affected 9.4, 3.5 and 3.2 times,
respectively. This indicated that these two parameters
of uncertainties were the most influential ones. The
other parameters such as duration of acute illness and
duration of persistent arthralgia could influence the
DALY estimates only 2.3 and 1.1 times respectively.
DALYs lost, per million population due to malaria,
leishmaniasis, lymphatic filariasis, dengue and Japa-
nese encephalitis for the year 1998 was 586, 1160,
2097, 359 and 67 respectively17. Current estimate of
burden of chikungunya was 45.26 per million, the
lowest among the vector-borne diseases.  The total
number of person days lost due to acute episodes of
chikungunya in the working age class were estimated
to be 7.4 million. Estimates of productivity loss in
terms of income foregone showed that it varied from
Rs. 5810 (West Bengal) to Rs. 214.4 million
(Karnataka). The total productivity loss was to the
tune of Rs. 391 million to the nation. The per capita
loss was Rs. 0.68 in the affected community.
Discussion
Chikungunya re-emerged in a massive scale with an
estimated number of 1.39 million fever/suspected
cases during 2006 in India, covering 213 districts in
15 states. About 565.42 million people were at the
risk of infection. The number of cases affected with
chikungunya would be more than that reported un-
der current surveillance system in India due to the
fact that a large proportion of the people consulted
private health care which were not reported and thus
lacked accuracy35.  Wide variation in the proportion
of laboratory confirmed cases suggest the issues re-
lated to diagnostic tools, procedure and quality con-
Table 3. Total DALYs, DALYs lost per million popula-
tion and productivity loss due to chikungunya
during 2006 epidemic in India
State Total Productivity DALYs lost
DALYs  loss  per million
lost population
Andhra Pradesh 1425 2,18,15,604 18.82
Karnataka 14,007 21,44,07,141 265.62
Maharashtra 4932 7,42,41,084 50.98
Tamil Nadu* 1191 1,94,48,521 19.18
Madhya Pradesh 1105 1,52,27,115 18.30
Gujarat 1397 2,13,87,086 27.61
Kerala 1300 2,08,96,259 40.84
A & N Islands 82 13,62,203 230.58
NCT of Delhi 10 1,62,816 0.75
Rajasthan 2 25,351 0.93
Puducherry** 10 1,65,208 13.55
Goa 5 90,173 3.93
Orissa 119 17,57,300 3.23
West Bengal 0 5810 0.00
Lakshadweep 1 9848 10.61
Total 25,588 39,10,01,519 45.26
*Out of total 40 administrative districts; **Affected district
population.
Fig. 2: Stratification of states in relation to DALYs due to
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trol including the time delay in sample collection.
Diagnosis related issues remain to be  major chal-
lenges in arboviral diseases as reported in dengue18.
Laboratory screening of every individual with sus-
pected chikungunya is neither feasible nor necessary
for treatment. Therefore, correction of suspected
clinical cases to the proportion of laboratory confir-
mation is not expected to influence the burden esti-
mates. However, the confirmation of cases is
necessary from the public health point of view to ini-
tiate disease specific control measures at community
level.
Several population based studies have assessed the
burden of dengue in different endemic countries and
the estimated DALYs lost ranged from 83.8 to 848
per million25,36–40.  Our current estimate of DALY
to express the epidemiological burden of chikungunya
is first of its kind.
In the absence of cause of death (CoD) information,
no death was attributed to chikungunya in India,
though reports of chikungunya related deaths were
reported elsewhere13.  But the morbidity and disabil-
ity caused due to chikungunya is enormous. The na-
tional burden was 45.26 DALYs lost per million
population due to 2006 epidemic in India.
Chikungunya imposed heavy burden in Karnataka,
with 266 DALYs lost per million followed by
Andaman and Nicobar Islands (231). Comparison of
DALYs lost per million population among the vector
borne diseases in India based on earlier estimates17
showed that lymphatic filariasis remained to be a
major public health concern. It imposes heavy burden
by contributing about 49% of the total 4294 DALYs
lost per million population in India due to vector borne
disease. The diseases in the order of their contribution
are leishmaniasis, malaria, dengue, JE and
chikungunya. Though the number of cases and the
attack rates were high (~38%)32, the contribution of
chikungunya in terms of DALY was the lowest. This
is because of its restricted outbreak with about 565
million people exposed to the risk of infection but with
no reporting of death attributable to chikungunya.
Though long-term arthralgia as extended morbidity
was reported in only 11.5% of the cases, its contri-
bution constitutes as high as 69% of the total 25,588
DALYs lost. It is mainly due to exceptionally longer
duration5,34 of this incapacitating symptom. It has
greater implication on health care to provide long-
term treatment for persistent arthralgia in addition to
economic loss.
The surveillance data used in the present estimate
have certain limitations. There was no age/gender
details, not all the fever/suspected cases were con-
firmed with diagnostic tests, and considerable pro-
portion of cases sought treatment from private health
facilities which were unknown as reported in other
cases35,41. The percentage of cases reporting to pri-
vate health care facilities during the epidemic in
Kerala was as high as 77.56% (personal observation).
Lack of clear case definitions and/or lack of its uni-
form application and absence of uniform reporting
system could result in lack of accuracy and poor re-
liability of surveillance data as reported earlier in
chikungunya35 and dengue18.  This may be the con-
sequence of not including this disease under “noti-
fiable” diseases.
Assumptions and incorporation of parameters with
uncertainties are inevitable in estimations. But it need
not be a constraint. Proportion of confirmed fever/
suspected chikungunya and under-reporting due to
seeking of health care from private health facilities
are the most influential parameters in DALY estima-
tion. Provision of facilities for laboratory confirma-
tion and inclusion of cases dealt within the private
sector could reduce the uncertainties in these param-
eters so as to make more realistic estimates of DALY.
GBD study group16 has derived age-specific disabil-
ity weight for DALY estimates for 107 health states
for different diseases26. There are a number of health
states that require disability weight values, including
chikungunya which presents two clear health states,
viz. acute (early stage of the infection) and chronic
(persistent arthralgia)5,22,42. Efforts are warranted to
derive disability weight for the clinical states of
chikungunya to facilitate realistic estimates ofKRISHNAMOORTHY ET AL: BURDEN OF CHIKUNGUNYA IN INDIA  33
DALYs.
Several reports that have emerged from the recent
outbreaks of chikungunya around the world32,35 will
be useful for better understanding of the epidemiol-
ogy of this infection. However, studies focusing on
risk factors43 are warranted to develop prediction
models and develop situation-specific measures of
epidemic preparedness. Vaccine is not currently
available against chikungunya. Therefore, vector
control remains a method of choice at least until a
potential and cost-effective vaccine is available for
large scale use. As the breeding of vector(s) is con-
fined to domestic and peri-domestic environment,
container management and source reduction may
eliminate vector breeding. This can be encouraged
through community participation with strong social
mobilization and communication component44 as it
is primarily a man-made problem at household level
as recommended for the control of dengue vec-
tors45,46. Since the known vectors of chikungunya
also transmit dengue47, vector control efforts could
offer protection against dengue also, which showed
an increased incidence of dengue haemorrhagic fe-
ver and dengue shock syndrome in India48. Thermal
fogging with appropriate insecticide should be re-
sorted to contain the epidemic. Vaccine research
needs to be encouraged as has been recommended
and justified for dengue25.
The current economic loss of Rs. 391 million due to
2006 epidemic of chikungunya in India can be con-
sidered as minimal as it used only minimum wage
and did not consider persistent arthralgia due to high
variability in its duration. The person days lost and
income foregone justifies allocation of funds towards
control/prevention of this disease. DALYs can also
serve as a measure to assess cost-effectiveness of
interventions against chikungunya but the number of
parameters with uncertainties should be minimal for
more realistic estimate. The important implication of
this study is that surveillance covering all vector
borne and zoonotic diseases needs  to be strengthened
for obtaining quality epidemiological data, apart
from justifying preventive measures to save DALYs.
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